Holding(s) in Company

For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuerof existing shares to which voting rights are Verona Pharma plcattached:ii 2. Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights √ An acquisition or disposal of qualifying financial instruments which may resultin the acquisition of shares already issued to which voting rights are attached An acquisition or disposal of instruments with similar economic effect toqualifying financial instruments An event changing the breakdown of voting rights Other (please specify): CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE √ RECENT SUBSCRIPTION, PLACING AND OPEN OFFER. 3. Full name of person(s)subject to the Aviva plc & its subsidiariesnotification obligation:iii Registered Holder: BNY Norwich Union Nominees Limited 4,817,119* Chase (GA Group) Nominees Limited 139,178,649*4. Full name ofshareholder(s) *denotes direct interest (if different from 3.):iv Chase (GA Group) Nominees Limited 15,111,869 Chase Nominees Limited 4,440,952 Vidacos Nominees Limited 18,701,411 5. Date of thetransaction and date onwhich the threshold is 25 March 2014crossed orreached: v 6. Date on which issuer 27 March 2014notified: 7. Threshold(s) that is/ 0% to 14% Change at Direct Interest Level andare crossed orreached: vi, vii 0% to 18% Change at Combined Interest Level 8. Notified details: A: Voting rights attached to shares viii, ix Class/type of Situation Resulting situation after the triggering transactionshares previous to the triggering transactionif possibleusing Number Number Number Number of voting % of voting rightsthe ISIN CODE of of of shares rights x Shares Voting Rights Direct Direct xi Indirect Direct Indirect xii Ordinary Shares NIL HELD NIL HELD 182,250,000 143,995,768 38,254,232 14.26% 3.79%GB00B06GSH43 B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of financial Expiration Exercise/ Number of voting % of votinginstrument date xiii Conversion Period xiv rights that may be rights acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying FinancialInstruments xv, xvi Resulting situation after the triggering transaction Type of Exercise Expiration Exercise/ Number of voting rights % of votingfinancial price date xvii Conversion instrument refers to rights xix, xxinstrument period xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 182,250,000 18.05% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi The voting rights are managed and controlled by Aviva Investors Global ServicesLimited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: Aviva plc (Parent Company) Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva GroupHoldings Limited) Aviva Investors Global Services Limited (wholly owned subsidiary of AvivaInvestors Holdings Limited) Proxy Voting: 10. Name of the proxy holder: See Section 4 11. Number of voting rights proxy holder will ceaseto hold: 12. Date on which proxy holder will cease to holdvoting rights: 13. Additional Figures are based on a total number of voting rights of 1,009,923,481,information: as per the Company's Result of General Meeting Announcement of 24 March 2014. 14. Contact Neil Whittaker, Aviva plcname: 15. Contacttelephone 01603 684420number: